Carisma Therapeutics Inc (CARM)
Carisma Therapeutics Inc is a biotechnology company listed on OTC Markets as common stock. The company is focused on developing therapies for liver fibrosis and cancer, with work centered on cell-based and gene therapy approaches. Its pipeline includes CT-2401, a preclinical candidate being studied for liver fibrosis, and CT-1119, a mesothelin-targeted CAR-Monocyte in phase I testing for advanced mesothelin-positive solid tumors such as pancreatic, ovarian, lung, and mesothelioma cancers. Carisma is also advancing an in vivo CAR-M cell therapy program for solid tumors, including hepatocellular carcinoma. The company has a collaboration and license agreement with ModernaTX, Inc. related to oncology gene therapies. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, it was formerly known as CARMA Therapeutics Inc. before changing its name in 2017.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CARM
|
$0.00090
|
-10.0% Downside
|
Fair
|
Not available
|
Not available
|
Good
|
0.0%
|
November 12, 2026
|
29.291 K
|
-1.982 M
|
94.8%
|
72.0%
|
-123.9
|
-278.7%
|
